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Abstract
β-Thalassemia, a hereditary blood disorder caused by reduced or absent synthesis of the
β-globin chain of hemoglobin, is characterized by ineffective erythropoiesis, and can manifest as
nontransfusion-dependent thalassemia (NTDT) or transfusion-dependent thalassemia (TDT).
Many patients with NTDT develop a wide range of serious complications that affect survival
and quality of life (QoL). Patient-reported outcomes (PRO), including health-related QoL
(HRQoL), are important tools for determining patient health impairment and selecting appropri-
ate treatment. However, there are currently no disease-specific PRO tools available to assess
symptoms related to chronic anemia experienced by patients with NTDT. This study aimed to
develop a new, US Food and Drug Administration (FDA)-compliant PRO of chronic anemia
symptoms, the NTDT-PRO© tool, for use in patients with NTDT. Participants had a median age
of 36 years (range, 18-47) and 60% were female. The initial development of the NTDT-PRO tool
involved concept-elicitation interviews with 25 patients from 3 centers (in Lebanon, Greece,
and Canada); subsequent interview discussions and clinical input resulted in the generation of
9 items for inclusion in the draft NTDT-PRO. Following a round of cognitive interviews involving
21 patients from 2 centers (in Lebanon and Greece), 4 items (Pain, Headaches, Ability to Con-
centrate, and Paleness) were removed from the draft NTDT-PRO. The final NTDT-PRO com-
prises 6 items that measure Tiredness, Weakness, and Shortness of Breath, with or without
Physical Activity. The NTDT-PRO is a new disease-specific HRQoL tool for patients with NTDT,
developed using a thorough methodology based on FDA 2009 PRO development guidelines.
1 | INTRODUCTION
β-Thalassemia is a hereditary blood disorder caused by reduced or
absent synthesis of the β-globin chain of hemoglobin and is character-
ized by ineffective erythropoiesis.1 Patients with β-thalassemia may
be classified as having either nontransfusion-dependent thalassemia
(NTDT) or transfusion-dependent thalassemia (TDT). Overall, the
treatment options for β-thalassemia patients are limited and focus on
symptomatic relief. For patients with TDT, this involves regular and
lifelong red blood cell (RBC) transfusions from the first months of life
along with iron chelation therapy. In contrast, treatment options for
patients with NTDT largely focus on the management of the long-†Former employee of Celgene Corporation.
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term complications of ineffective erythropoiesis, which are not elimi-
nated through suppression of erythropoiesis by chronic transfusion
protocols, as in TDT patients.2,3 Treatment options targeting NTDT
and its complications are limited and include splenectomy, RBC trans-
fusions, iron chelation therapy, and hydroxyurea in some cases.4 A
novel therapeutic agent, luspatercept (under development by Celgene
Corporation, Summit, NJ, USA) is in phase 3 clinical development for
the treatment of patients who require regular RBC transfusions due
to β-thalassemia (Piga et al., manuscript submitted for publication).
Despite the increased transfusion burden associated with TDT
and perception of increased disease severity in comparison with
NTDT, most patients with NTDT also develop an array of serious
complications that compromise survival and health-related quality of
life (HRQoL). Such complications include activity-limiting anemia,
bone pain, low bone density, leg ulcers, pulmonary hypertension,
silent cerebral ischemia, and renal disease.4,5 These patients may also
have low levels of hemoglobin, which is associated with a reduced
HRQoL,6 compounding the fact that the therapy required to treat
NTDT and its complications may also have a negative impact on
patient HRQoL.3
Patient-reported outcome (PRO) measures, including HRQoL, are
important tools for determining patient health impairment and select-
ing appropriate treatment. Although disease-specific PRO question-
naires have been developed for patients with TDT (TranQol7; Specific
Thalassemia Quality of Life Instrument, STQOLI8), there are currently
no disease-specific PRO tools available to assess symptoms related to
chronic anemia experienced by patients with NTDT.
Regulatory agencies, such as the US Food and Drug Administration
(FDA) and the European Medicines Agency (EMA), have expressed inter-
est in the use of disease-specific PROs in establishing product efficacy
and safety, as well as in documenting the patient's experience of their ill-
ness and treatment. The qualitative research described here is a first step
in generating a NTDT-specific symptom PRO tool and it follows 2009
FDA industry guidelines for the development of PRO tools.9 It is also
consistent with expert guidelines for the development of PRO tools in
the medical product development context.10
The objective of the present study was to develop a new PRO
tool, the NTDT-PRO©, for use in patients with NTDT.
2 | METHODS
2.1 | Development of the NTDT-PRO tool
A qualitative study was carried out to develop the NTDT-PRO tool,
consistent with regulatory and expert guidance. Development was
carried out in four stages: concept elicitation, item generation, cogni-
tive interviews, and modification (Figure 1).
Interviews were conducted in the native language of each patient
by trained interviewers and audio-recorded. Transcripts were subse-
quently translated into English for analysis.
2.1.1 | Stage 1: Concept elicitation
To identify symptoms associated with NTDT and determine the impact
of those symptoms on patients with NTDT, a cross-sectional, qualitative,
concept-elicitation-interview study was carried out with patients
recruited from 3 centers in Lebanon, Greece, and Canada; local institu-
tional review board (IRB) approval was obtained for all 3 centers. Patients
who were ≥18 years of age and presented with a NTDT diagnosis, con-
firmed by clinical chart review, were eligible to participate; eligible
patients were invited to participate in a face-to-face interview at their
local clinical center. Interviews were conducted by trained interviewers
and were carried out using a standardized, semi-structured discussion
guide, which was developed based on a literature review and findings
from a Delphi panel of 7 clinical experts. The patient interviews were
conducted in 2 parts: during the first part, patients were asked open-
ended questions to gather information about their symptom experiences
and the impact of NTDT on their symptoms and functioning; the second
part of the interview focused on specific symptoms, identified by the
Delphi panel and a literature review, which had not been mentioned dur-
ing the first part of the interview. Clinical center staff completed a form
for each patient, recording pertinent data of their clinical history, includ-
ing the date of diagnosis, medication history, and complications of NTDT.
Each interview lasted approximately 90 min.
2.1.2 | Stage 2: Item generation and data analysis
The aim of stage 2 was to develop a draft NTDT-PRO instrument,
based on the concept-elicitation interviews conducted during stage
1. Quantitative data (sociodemographic and clinical data, 36-Item
Short Form Health Survey version 2 [SF-36v2], and Functional
Assessment of Cancer Therapy-Anemia [FACT-An]) responses were
stored in a database that was developed, tested, and validated using
DataFax (an optical character-recognition software; Clinical DataFax
Systems, Inc., Hamilton, ON, Canada) and reviewed by project scien-
tific staff. Data discrepancies were identified and resolved prior to
being summarized using descriptive statistics.
Qualitative data from the transcripts were summarized using
ATLAS.ti qualitative data analysis software (ATLAS.ti v.7.1.8; ATLAS.ti
GmbH, Berlin, Germany). A content-analysis approach was used to
analyze qualitative data, and a coding scheme was created based on
the structure and content of the discussion guide. Concepts identified
during each concept-elicitation interview were analyzed with the aim
of comparing and quantifying the amount of novel information
observed in each subsequent interview; overall saturation occurred
when no novel information emerged from subsequent interviews. Key
symptoms were identified based on prevalence and perceived impor-
tance for patients interviewed. Based on these data, the NTDT-PRO
version 1 (NTDT-PRO.v1) was created to assess the severity of NTDT
from a patient perspective.
A conceptual framework, depicting domains and possible scoring,
was developed and modified during the development of the NTDT-
PRO instrument.
2.1.3 | Stage 3: Cognitive interviews
Cognitive interviews were carried out using the NTDT-PRO.v1 to
ensure the content of the tool captured all relevant symptoms, was
understandable by patients, and included suitable response options
and recall period. This stage was also designed to identify any
necessary modifications required to produce a final version of the
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NTDT-PRO. A cross-sectional qualitative interview study was con-
ducted with patients from 2 clinical centers in Lebanon and Greece;
these were the same centers used in the concept-elicitation phase,
and IRB approval was obtained for both centers.
To ensure consistency between stages, the same eligibility criteria,
patient recruitment methods, and data collection processes were used as
during stage 1 (concept elicitation). Eligible patients were invited to a
face-to-face interview at their local clinical center. Due to the rarity of
the disease, patients were permitted to participate in both concept-
elicitation interviews and cognitive interviews, although different patients
were preferred. Patients were subsequently asked to complete the
NTDT-PRO.v1. Interviews were then conducted using a standardized
semi-structured discussion guide focusing on the discussion of instruc-
tions, content and formatting of individual items, response options, and
recall period.
Sociodemographic and clinical information was collected as in the
concept-elicitation interviews. Descriptive statistics were used to
summarize clinical characteristics, and quantitative data from the
NTDT-PRO.v1 and the sociodemographic questionnaire.
Qualitative data from cognitive interviews were assessed using
ATLAS.ti; a programming workflow was generated to analyze the
structure and content of the discussion guide; understanding of the
instructions, questionnaire content, symptom recall period, and ques-
tion response options were evaluated for each item. Degree of under-
standing was assessed for each item; patients' comments for
improvement were coded separately.
2.1.4 | Stage 4: Modification based on cognitive
interviews
The final stage involved identification and implementation of updates
to the NTDT-PRO.v1, based on findings from cognitive interviews
and clinical input.
3 | RESULTS
3.1 | Concept-elicitation interviews
A total of 25 patients from the centers in Lebanon (n = 13), Greece
(n = 7), and Canada (n = 5) were included in the concept-elicitation
interviews; demographic and clinical characteristics are presented in
Table 1.
The most frequent complications included bone disease (n = 16),
cholelithiasis (n = 10), deep vein thrombosis (n = 7), extramedullary
hematopoiesis (n = 4), and ulcers on the lower extremities (n = 4);
2 patients (8%) did not report complications. Splenectomy was
reported in 20 patients.
Based on the concept-elicitation interviews, a total of 11 distinct
symptoms were identified among patients (descending order of
reported frequency): tiredness/fatigue (88%), weakness (80%), breath-
lessness (80%), pain (72%), headaches (72%), skin pallor (68%), sleep
problems (60%), cognitive impairment (52%), dizziness/lightheaded-
ness (32%), chest problems (28%), and sexual problems (19%).
Of the 25 patients interviewed, 21 (84%) patients reported physi-
cal impacts as a result of their disease, and 18 (72%) patients reported
that their daily activities were limited as a result; impact on work or
school life was reported by 17 (68%) patients. Additionally, 15 (60%)
patients reported anxiety and 15 (60%) patients reported that their
disease had an impact on their social life.
3.2 | Item generation
Based on findings from the concept-elicitation interviews, the NTDT-
PRO.v1 was developed. The NTDT-PRO.v1 included 9 items assessing
the following symptoms: Tiredness without Physical Activity, Tired-
ness with Physical Activity, Weakness, Shortness of Breath (SoB)
CONCEPT ELICITATION
(Stage 1)
Greece (n = 7) 
Lebanon (n = 13) 
Canada (n = 5) 
ITEM GENERATION: 
NTDT-PRO© VERSION 1 
(Stage 2)  
COGNITIVE INTERVIEWS 
(Stage 3) 
Lebanon (n = 15) 
Greece (n = 6) 
MODIFICATION: 
NTDT-PRO© VERSION 2 
(Stage 4) 
FIGURE 1 Study chronology. NTDT-PRO©, nontransfusion-dependent thalassemia patient-reported outcomes symptom measure
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without Physical Activity, SoB with Physical Activity, Worst Pain,
Headaches, Ability to Concentrate, and Paleness. An 11-point numeri-
cal rating scale, ranging from 0 (“no symptom”) to 10 (“very extreme
symptom”) was used for each item. The items asked the patient to
consider their experience over the past 24 hours when responding.
3.3 | Cognitive interviews
A total of 21 patients, 15 from 1 center in Lebanon and 6 from 1 cen-
ter in Greece, participated in 2 rounds of cognitive interviews; sum-
marized demographic and clinical characteristics are presented in
Table 1. A total of 13 patients (8 of the 15 patients recruited in Leba-
non and 5 of the 6 patients recruited in Greece) took part in both the
concept-elicitation stage and the cognitive-interview stage of the
study.
The items covering Worst Pain and SoB without Physical Activity
showed a notable floor effect—47% and 62% of patients rating these
outcomes as 0, respectively. The remainder of items showed a good
distribution of reported values across the 0-10 range, with responses
in the lower two-thirds of the scale seen most frequently.
Mean item scores for the NTDT-PRO.v1 ranged from 1.2
(Headaches) to 4.2 (Tiredness with Physical Activity) (Table 2). All
patients reported that the instructions in the NTDT-PRO.v1 were
clear and easy to understand. The 24-hr recall period was understood
and easily adhered to by all patients who were specifically asked the
question (n = 21).
Overall, patient comprehension reflected the intended meaning
of the items. However, 5 patients did not understand the question
relating to “SoB while not engaging in physical activity,” largely due to
variation in patient definitions of “no physical activity” (eg, from “not
doing anything” to “not running errands”). A few patients (3/21, 14%)
found the question on weakness ambiguous, due to a lack of clarity
regarding whether the item referred to physical weakness, or emo-
tional, psychological, intellectual, social, or personality weakness;
some patients also highlighted that they were already weak (ie, “Weak
physically. We are already weak, I mean we are not healthy, we do
not have a strong body”). Additionally, although the majority of the
patients understood the question on skin pallor, several patients erro-
neously reported “yellowness” due to jaundice, rather than “paleness”
due to anemia.
No additional symptoms were identified during the cognitive
interviews.
3.4 | Modifications based on cognitive interviews
Based on patient and clinical input gained during the cognitive-
interview stage, the NTDT-PRO.v1 was revised as follows: attribution
of the symptoms to NTDT was removed from the patient instructions,
as FDA guidance states that patients may not be able to attribute
symptoms to their condition; items related to tiredness and SoB were
removed or rephrased to include reference to physical activity; Weak-
ness was revised to Physical Weakness for improved clarity; 4 items
were deleted (Worst Pain, Headaches, Ability to Concentrate, and
Paleness). Worst Pain was removed from the NTDT-PRO.v1 as it was
unclear whether this was a symptom of NTDT or a complication
related to treatment, and it was felt that this would be better captured
as an adverse event. Headaches, Ability to Concentrate, and Paleness
were removed as tool items as they were not considered to be core
symptoms (ie, distal to NTDT). These symptoms were also less fre-
quently reported by patients, which contributed to the decision to
exclude these 4 items initially included in the conceptual framework.
3.4.1 | NTDT-PRO and conceptual framework
Based on the findings of the patient interviews, a 6-item revised
NTDT-PRO.v2© instrument was developed (Appendix and Table S1 of
the Supporting Information). The NTDT-PRO was designed as a daily
diary with recall of thalassemia-related symptoms over the previous
24 hr. The relatively short recall period was chosen due to the high
TABLE 1 Demographic and clinical characteristics
Patient characteristic
Concept-
elicitation
cohort (n = 25)
Cognitive-
interview
cohort (n = 21)
Median age (range), years 36 (18–47) 37 (23-45)
Female, n (%) 15 (60.0) 11 (52.4)
Thalassemia diagnosis, n (%)
β-Thalassemia intermedia 23 (92.0) 21 (100)
HbE/β-thalassemia 2 (8.0) 0
Median time since diagnosis
(range), years
29.0 (17-47) 28.0 (12-45)
Hospitalization in last 3 months,
n (%)
2 (8.0) 2 (9.5)
Number of NTDT complications, n (%)
<3 14 (56.0) 14 (66.7)
3-5 9 (39.1) 5 (23.8)
≥6 0 2 (9.5)
Highest education level, n (%)
Primary/elementary 2 (8.0) 2 (9.5)
Secondary/high school 7 (28.0) 8 (38.1)
College/university 14 (56.0) 8 (38.1)
Unknown/other 2 (8.0) 3 (14.3)
Abbreviations: HbE, hemoglobin E; NTDT, nontransfusion-dependent
thalassemia.
TABLE 2 NTDT-PRO©.v1 item scores
Cognitive-interview
Cohort (n = 21)
Tiredness without Physical Activity 3.2 (2.7)
Tiredness with Physical Activity 4.2 (2.6)
Weakness 3.4 (2.6)
Shortness of Breath without Physical Activity 2.0 (3.1)
Shortness of Breath with Physical Activity 3.3 (2.4)
Worst Pain 2.4 (2.5)
Ability to Concentrate 2.7 (2.5)
Headaches 1.2 (2.0)
Paleness 3.9 (2.9)
Values shown are mean (SD) NTD-PRO.v1 item scores; severity range
0 (no) to 10 (high).
NTDT-PRO©.v1, nontransfusion-dependent thalassemia patient-reported
outcomes measure, version 1; SD, standard deviation.
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level of day-to-day variation in symptoms experienced by patients
with NTDT.
The 6 NTDT-PRO items assessed the presence or severity of spe-
cific symptoms using a numerical rating scale ranging from 0 (“absent/
minimal”) to 10 (“extreme/high”): Tiredness with or without Physical
Activity, Weakness with or without Physical Activity, and SoB with or
without Physical Activity.
NTDT-PRO items were grouped a priori into 2 domains, based on
the conceptual framework (Figure 2): Tiredness/Weakness (Tiredness
with Physical Activity, Tiredness without Physical Activity, Weakness
with Physical Activity, and Weakness without Physical Activity) and
SoB (SoB with Physical Activity, SoB without Physical Activity).
4 | DISCUSSION
General anemia/HRQoL instruments may not be useful for patients
with NTDT as they do not include the individual patient experience of
symptom severity. Disease-specific HRQoL PRO tools are currently
available for patients with TDT.7,8 However, available TDT tools, such
as the TranQol7 and STQOLI,8 are not appropriate for patients with
NTDT; patients with TDT receive transfusions more frequently, and
report a higher frequency of hospitalization, resulting in a different
impact on HRQoL and perceived burden of disease. Furthermore, the
treatment pathways and disease progression are not equal for
patients with TDT and NTDT. As the impact of thalassemia on HRQoL
is perception-based, there is a need for a PRO HRQoL tool to deter-
mine NTDT patients' individual physical and social requirements.
The primary objective of this study was to develop the first
disease-specific PRO tool to assess reported symptom severity in
patients with NTDT. In the present study, we defined the item selec-
tion and evaluated the appropriate analyses for NTDT-PRO. Patients
were recruited from multiple geographic and socioeconomic back-
grounds to increase the generalizability of the tool content, demon-
strating evaluation and testing of this tool on a diversified patient
cohort. Patients who received RBC transfusions (<5 units in the previ-
ous 24 weeks to allow for RBC degradation) were excluded, as they
may not exhibit the full symptom range seen in NTDT patients. In
addition, a threshold of less than 10 g/dL hemoglobin was set to
ensure faithful recapitulation of low tissue oxygen delivery. To ensure
applicability, the NTDT-PRO was developed in multiple languages
(Italian, Greek, Arabic, and English); however, this may have contrib-
uted to the misunderstanding in physical versus emotional weakness.
Modifications were also required to account for nonmedical interpre-
tation of skin pallor, as this was interpreted by some patients as jaun-
dice. To ensure clarity and understanding among the target patient
population, 2 rounds of cognitive interviews were conducted among
patients with NTDT in Greece and Lebanon. While findings from
these cognitive interviews indicated that participants understood the
items as intended, there may be a need for future translations that
take more account of cultural considerations.
The NTDT-PRO was developed using concept-elicitation inter-
views, interview discussions, cognitive interviews, and clinical input.
Compared with existing tools for evaluating HRQoL in patients with
TDT (ie, TranQol), the NTDT-PRO is considerably shorter, comprising
6 items across 2 domains (Tiredness/Weakness and SoB) in addition
to an overall severity score, versus 37 items over 4 domains for the
adult form of the TranQol,7 and 28 items over 4 domains for the
STQOLI.8 This is important as it provides patients with a PRO tool to
quickly report on their disease severity, allowing symptom reporting
with higher sensitivity for the prescribing physician. One of the key
findings from the development of the TranQol was the difference in
the reported HRQoL priorities between patients with TDT and other
patient groups, that is, relating to the disease-specific impact of thal-
assemia, and to the impact and risks associated with frequent transfu-
sions.7 There are a number of limitations associated with this study.
As this was a noninterventional study, there are no data on the perfor-
mance of the NTDT-PRO tool in response to treatment interventions.
There are also limited data on the performance of the tool in different
settings, such as community-based centers versus academic research
centers, and how the tool can be generalized to a real-world setting
(ecological validity).
Quantitative analysis to support the reliability and validity of the
NTDT-PRO tool has been performed in an observational, noninter-
ventional study (NCT02626689) (Taher et al, manuscript submitted
for publication); however, future studies will be required to confirm
the psychometric properties of the NTDT-PRO and its sensitivity in
capturing changes. Additional assessment of what constitutes a mini-
mal clinically important difference in interventional clinical trials is cur-
rently ongoing. We hope this tool will provide researchers with a
more appropriate measure of the impact NTDT has on the HRQoL of
FIGURE 2 Conceptual framework. SoB, shortness of breath
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patients affected, both in daily clinical practice and in multicenter trials
of novel interventions for patients with NTDT.
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